# US 2023/0069813 A9 · Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional Supplement

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069813 A9
- Document ID: US20230069813A9
- Status: Published application
- Kind: A9
- Application number: 17/558,763
- Filed: 2021-12-22
- Published: 2023-03-02
- Earliest claimed: 2007-06-26
- Assignees: JDS Therapeutics, LLC
- Applicants: JDS Therapeutics, LLC
- Inventors: James R. Komorowski
- Web page: https://patentgrep.com/patent/US20230069813A9

## CPC

- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A23L 33/15: Vitamins
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A dosage form for oral administration comprising:
an inner therapeutic agent;
a middle barrier layer disposed over the therapeutic agent, wherein the therapeutic agent is an anti-oxidant, anti-inflammatory, or combinations thereof; and
an outer nutritional supplement layer disposed over the barrier layer, wherein the nutritional supplement comprises one or more of a linoleic acid, an herbal extract, a botanical extract, or a combination thereof;
wherein said inner therapeutic agent and outer nutritional supplement layer are formulated as a single dose.

### Claim 22 (depends on 21)

The dosage form of claim 21, wherein the therapeutic agent is provided in a therapeutically effective amount.

### Claim 23 (depends on 21)

The dosage form of claim 21, wherein the barrier layer is comprised of a controlled-release, delayed-release, or enteric coating.

### Claim 24 (depends on 21)

The dosage form of claim 21, wherein the dosage form is provided as a fast dispersing form.

### Claim 25 (depends on 21)

The dosage form of claim 21, further comprising an outer coating.

### Claim 26

A dosage form for oral administration comprising:
an inner therapeutic agent layer;
a middle barrier layer disposed over the therapeutic agent layer, wherein the therapeutic agent layer comprises one or more of an anti-oxidant, anti-inflammatory, or combinations thereof; and
an outer nutritional supplement layer disposed over the barrier layer, wherein the nutritional supplement comprises one or more of a linoleic acid, an herbal extract, a botanical extract, or a combination thereof;
wherein said inner therapeutic agent layer and outer nutritional supplement layer are formulated as a single dose.

### Claim 27 (depends on 26)

The dosage form of claim 26, wherein the therapeutic agent is provided in a therapeutically effective amount.

### Claim 28 (depends on 26)

The dosage form of claim 26, wherein the barrier layer is comprised of a controlled-release, delayed-release, or enteric coating.

### Claim 29 (depends on 26)

The dosage form of claim 26, wherein the dosage form is provided as a fast dispersing form.

### Claim 30 (depends on 26)

The dosage form of claim 26, further comprising an outer coating.

### Claim 31

A dosage form for oral administration comprising:
an inner therapeutic agent;
a middle barrier layer disposed over the therapeutic agent; and
an outer nutritional supplement layer disposed over the barrier layer, wherein the nutritional supplement comprises one or more of a linoleic acid, an herbal extract, a botanical extract, or a combination thereof;
wherein said inner therapeutic agent layer and outer nutritional supplement layer are formulated as a single dose.

### Claim 32 (depends on 31)

The dosage form of claim 31, wherein the therapeutic agent is provided in a therapeutically effective amount.

### Claim 33 (depends on 31)

The dosage form of claim 31, wherein the barrier layer is comprised of a controlled-release, delayed-release, or enteric coating.

### Claim 34 (depends on 31)

The dosage form of claim 31, wherein the dosage form is provided as a fast dispersing form.
The dosage form of claim 31, further comprising an outer coating.
